Novo Integrated Sciences Reports 2024 Fiscal Year Financial Results
Novo Integrated Sciences Ends $60M Gemstone Deal
Novo Integrated Sciences GAAP EPS of -$0.74, revenue of $3.15M
Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results
NVOS Stock Earnings: Novo Integrated Sciences Reported Results for Q3 2024
Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program
Novo Integrated Sciences Announces Major Funds Disbursement
Novo Integrated Sciences: A Coil Spring Ready To Explode
Novo Integrated Sciences Secures Leadership Until 2025
Novo Integrated Sciences Receives Confirmation of Issuance of SBLC by HSBC for SBLC Leasing and Monetizing Program
Novo Integrated Sciences Secures $78 Million Funding via HSBC
Novo Integrated Sciences’ Board of Directors Approves Increase of Maximum Amount Under Stock Repurchase Program to $10 Million
Novo Integrated Sciences Doubles Stock Buyback Program
Novo Integrated board boosts maximum amount under stock buyback to $10M
Acenzia Selected to Participate in Protein Industries Canada Program to Develop Plant Based Protein Products
Novo Integrated Sciences Ventures into Global Protein Market
Novo Integrated Sciences and RC Consulting Consortium Group Amend $70,000,000 Promissory Note
Novo Integrated Sciences Amends Promissory Note Terms
Day Trading During A Slow Holiday Week
Novo Integrated Sciences’ Board of Directors Conducting Strategic Review to Increase Maximum Amount under Stock Repurchase Program
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.